Urgent recall warning for popular Biscoff-flavoured ice cream
Cheshire Farm is recalling batches of its Caramelized Biscuit Ice Cream and Biscoff Ice Cream because they contain hazelnuts. The FSA, which published the alert, said the products are a 'possible health risk for anyone with an allergy to nuts.'
The recall only impacts its one litre tubs and three different batch codes. One of these included the Caramelized Biscuit Ice Cream Pack with the code L24150, best before 29 November 2025.
The other recall accounted for the Biscoff Ice Cream Pack with batch codes 23139 and L23261 with best before dates 19 November 2024 and 18 March 2025.
According to the organisation, the farm contacted 'relevant allergy support organisations, which will tell their members about the recall.'
The company has also issued a point-of-sale notice to its customers to explain why the product was being recalled and tell them what to do if they have purchased the product.
It's understood that despite including the name 'Biscoff' on the label, the ice creams are not affiliated with the Lotus Biscoff brand and do not contain Biscoff products.
The FSA asked customers who had bought the products and have an allergy to nuts not to eat it.
It said: 'Instead return it to the store from where it was bought for a full refund. For more information, please contact Cheshire Farm at: info@cheshirefarmicecream.co.uk.'
Allergy UK estimate that tree nut allergies affect two per cent of children and 0.5 per cent of adults in the UK. Those with existing peanut allergies have an increased likelihood of around 30-40 per cent of developing a tree nut allergy.
While it's most common to develop a nut allergy before the age of five, it's also possible for older children and adults to develop allergic symptoms.
Symptoms of an allergic reaction can vary; they can occur within minutes of contact or up to two hours later. While most allergic reactions are mild, for some people they can be more moderate or severe, with anaphylaxis being the most severe form of reaction, which can be life threatening.
Cheshire Farm produces an 'extensive range of quality real dairy ice creams, fruit sorbets and vegan products' in more than 40 flavours with over 25 non-dairy options.
The farm was founded in 1984 by Tom and Margaret Fell, when they moved to Drumlin Hall Farm with two sons, Graeme and Jonathan. More than 40 years later, they have gone on to make multi-award-winning ice cream. The Ice Cream Farm is a popular visitor attraction in Chester that holds the Guinness World Record for being the 'largest ice cream shop in the world'.
The Independent has reached out to Cheshire Farm for comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
UK Food Safety Testing Market Size to Reach US$2.8 Billion by 2033
Shaped by strict Food Standards Agency (FSA) regulations and post-Brexit import complexities, the UK market emphasizes robust allergen management and supply chain traceability. High consumer awareness and advanced rapid testing methods are integral to maintaining confidence. Chicago, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The UK food safety testing market was valued at US$ 1,306.23 million in 2024 and is expected to reach US$ 2,801.82 million by 2033, growing at a CAGR of 9.23% during the forecast period 2025–2033. A dramatic surge in foodborne pathogens is a primary catalyst for growth. The frequency and scale of recent outbreaks are alarming. Official data show 70,352 laboratory-confirmed cases of Campylobacter in England during 2024, marking a decade-long high. Similarly, Salmonella infections in England peaked at 10,388 reported cases in 2024. Specific outbreaks highlight the severity of the situation. A 2024 Salmonella Blockley event resulted in 54 cases across the UK. These cases were distributed with 36 in England, 11 in Scotland, and 7 in Wales. The outbreak led to the hospitalization of ten individuals. Download Sample Pages: Even more concerning was a major Shiga toxin-producing E. coli (STEC) O145 outbreak in summer 2024, which caused over 250 illnesses in the UK food safety testing market. By late June 2024, confirmed cases reached 275. The geographical breakdown shows 182 cases in England, 58 in Scotland, and 31 in Wales. The outbreak's severity is underscored by the 122 people hospitalized. Furthermore, seven confirmed cases of haemolytic uraemic syndrome (HUS) were directly linked to the STEC O145 event. The Food Standards Agency (FSA) is actively investigating an increased number of incidents. Investigations into Listeria-related outbreaks grew to 17 in the 2024/25 period. STEC-related outbreak investigations rose to 13, and Salmonella outbreak investigations increased to 11 in the same timeframe. Adding to the domestic pressure, 2,703 cases of travel-associated gastrointestinal infections were recorded in England in 2024, with 183 of these being travel-related STEC infections. Key Findings in UK Food Safety Testing Market Market Forecast (2033) US$ 2,801.82 million CAGR 9.23% By Test Method Microbiological Test (36.64%) By Product Type Processed Food (25.56%) By Containment Type Biological Contaminants (36.85%) By Technology Traditional Testing (54.63%) By Service Sourcing Inhouse (57.75%) By Application Pathogen Detection (44.03%) By End User Food & Beverage (66.6%) Top Drivers Stringent post-Brexit import controls require comprehensive testing regimes. High consumer demand for transparency and clean-label products. Growth of plant-based and free-from food categories necessitates testing. Top Trends Adoption of whole-genome sequencing for precise outbreak source tracking. Focus on developing rapid tests for emerging environmental contaminants. Increased use of data analytics for predictive risk modeling. Top Challenges Navigating regulatory divergence between the UK and the EU. Persistent labor shortages impacting food industry and laboratory staffing. Combatting sophisticated food fraud and economically motivated adulteration. Chemical Contaminant Risks Mandate Broader and More Sophisticated Testing Protocols The threat is not limited to pathogens; chemical contaminants demand equal attention in the UK food safety testing market. Growing concerns over pesticides, industrial chemicals, and mycotoxins are expanding the required scope of testing services. In 2024, the FSA issued 14 food alerts for metal contamination alone, with 4 of these occurring by April. Analysis of imported food revealed residues of 48 pesticides not approved for use in the UK. A deeper look found residues from 46 cancer-linked pesticides in imported produce. In comparison, 19 cancer-linked pesticides were detected in food originating from the UK in 2024. The issue of "forever chemicals" has become prominent. A 2024 analysis discovered 10 different PFAS pesticides in fruit and vegetables sold in the UK food safety testing market. The nation currently approves 25 PFAS pesticides for use, with 6 of them classified as 'highly hazardous'. Government testing confirmed the presence of PFAS chemicals in over 3,300 food and drink samples in 2024. These findings came from a program that tested approximately 3,000 samples of food and produce. Meanwhile, the UK's annual testing for heavy metals covers a mere 400 to 450 samples of meat, milk, fish, and honey. A potential source of contamination is the UK's over 8,500 abandoned mines, which can leach toxic metals into the food chain. Specific food surveys also raise red flags. In a 2024 retail food survey, 13 out of 30 soy samples tested contained elevated levels of the mycotoxin ochratoxin A. A separate test of 90 samples for physical contaminants found one sample to be non-compliant. Escalating Product Recalls and Allergy Alerts Underscore Critical Testing Needs The sheer volume of product recalls provides a stark indicator of systemic weaknesses. These events in the UK food safety testing market are not only more frequent but also larger in scale, fuelling investment in preventive testing. In 2024, just three large-scale recall alerts implicated a staggering 424 different products. The average number of products recalled per event in 2024 was 2.5 times higher than in 2023. In the 2023/24 period, the FSA and Food Standards Scotland (FSS) issued a combined total of 136 food alerts. Within that total, 66 were specific Allergy Alerts. The focus on allergens intensified significantly, with 101 Allergy Alerts issued by the FSA and FSS in 2024. Beyond allergens, there were 67 product recalls in 2024 due to issues like foreign bodies and microbial contamination. The problem is widespread. In the first quarter of 2025, a total of 1,242 food and beverage recalls were recorded across the EU and UK. Non-bacterial contamination was responsible for 550 of these recalls. Aflatoxins were the culprit in 135 recall events. Bacterial contamination led to 237 recalls, with Salmonella being the cause of 174 of those incidents. Undeclared allergens prompted 94 recalls in Q1 2025, with milk being the most frequent issue, causing 19 separate recalls. Such figures make a compelling case for the expanding UK food safety testing market. Strict Regulatory Enforcement and Incident Management Spur Compliance-Driven Testing Demand Regulatory bodies are intensifying their oversight, making robust testing a non-negotiable aspect of compliance. The FSA's incidents response unit managed 1,837 food and feed incidents in the 2023/24 financial year. In the subsequent 2024/25 period, the FSA received notifications for 1,825 incidents across England, Wales, and Northern Ireland. Beyond direct notifications, the agency monitored 12,504 food safety signals in 2024/25. These signals prompted 810 intelligence assessments, which in turn launched 36 new investigations. Ultimately, these monitored signals resulted in 18 new incidents that required product withdrawal from the market. Local authorities are also increasing formal enforcement actions, which rose to 5,898 for food hygiene in 2023/24. Actions related to food standards in the food safety testing market grew to 658 in the same period. The financial consequences of non-compliance are severe. In a high-profile 2024 case, retailer ASDA was fined £640,000 for selling over 100 out-of-date food items. Asda was also ordered to pay an additional £15,115 in prosecution costs. The case was not an isolated one; it followed two other 2024 instances where Asda was fined £250,000 and £410,000 for similar food safety breaches. These penalties send a clear message to the industry. Specialized Food Crime and Fraud Investigations Are Now Major Market Drivers A growing area of focus is the criminal threat to the food supply chain. Specialized units are actively tackling food fraud, creating a niche for advanced authenticity and integrity testing. The UK's food crime units were running 29 live investigations during 2024. A significant portion of these, 20 investigations, involved meat and meat products. The scale of these operations is considerable. In a single food crime case in November 2024, officers seized 48 illegal sheep carcasses. As part of that National Food Crime Unit (NFCU) investigation into illegal meat, five men were arrested in London. The NFCU is also securing financial penalties against perpetrators. In a 2025 case, the unit obtained a confiscation order of over £30,000 from an individual selling illegal 'smokie' meat products. The action marked the third high-profile 'smokie' meat fraud case pursued by the NFCU within a single year. These enforcement successes highlight the critical need for sophisticated testing solutions that can verify the origin, composition, and legality of food products, a key growth area for the UK food safety testing market. Strained Local Authority Resources Create Significant Gaps in Public Food Safety While regulatory demands are increasing, the capacity of public enforcement bodies is strained. Under-resourced local authorities in the UK food safety testing market are struggling to maintain oversight, shifting a greater burden of responsibility onto businesses and their internal testing programs. As of 2024, there is a backlog of 95,000 overdue food business inspections across England, Wales, and Northern Ireland. Worryingly, this backlog includes 871 businesses classified as high-risk. In Scotland, 12,533 registered food businesses remained unrated as of December 2024. The number of unrated establishments awaiting a first inspection in England, Wales, and Northern Ireland had grown to around 41,000 by April 2024. This resource strain is directly impacting surveillance. The total number of food samples taken by local authorities across the UK dropped to 37,911 in the 2023/24 period. This figure is down from 40,144 samples in the prior period, showing a continuing decline in public testing capacity. Concurrently, consumer complaints are rising. There was an increase of 1,540 consumer complaints related to food hygiene in 2023/24, reaching a total of 60,919. Complaints regarding food standards and authenticity also rose by 200, to a total of 11,188 in the same period. Competitive Landscape Heats Up as Key Players Expand to Meet Demands Leading providers in the UK food safety testing market are responding to these challenges with strategic expansions and innovations. Key players are enhancing their capabilities to capture growing demand, particularly in identified hotspot sectors. In July 2025, Eurofins Food Testing UK demonstrated a clear growth strategy by finalizing its acquisition of the Bio Search food testing laboratory in Belfast. The move significantly expands its capabilities and footprint in Northern Ireland. In 2024, Eurofins also launched a new method for enumerating acetic acid bacteria, a service specifically targeting the needs of the UK beverage industry. These expansions are timely, as certain food categories are under intense scrutiny. A 2024 FSA survey found that 16 out of 40 samples of frozen raw chicken, a total of 40%, were non-compliant due to issues like undeclared water. The same survey revealed that 10 out of 24 frozen beef burger samples, or 42%, were non-compliant. Among the non-compliant burger samples, eight were found to have less meat content than what was declared on the label. These sector-specific failings create clear opportunities for specialized testing services. Advanced Whole Genome Sequencing Technology Revolutionizes Outbreak Response and Investigation The evolution of the UK food safety testing market is intrinsically linked to technological advancement. While widespread adoption rates are proprietary, official reports confirm the critical role of next-generation methods. Advanced testing technologies, particularly whole genome sequencing (WGS), are no longer on the horizon; they are central to modern surveillance and response. The UK Health Security Agency (UKHSA) extensively used WGS to successfully identify and manage the 2024 outbreaks of Salmonella Blockley and E. coli O145. The application of WGS in these high-profile incidents demonstrates the technology's power. It allows for a level of precision in linking cases and identifying the source of an outbreak that was previously impossible. This capability is transforming public health investigations. The clear success and growing reliance on WGS signal a market-wide shift. The move is away from traditional culturing methods and toward more rapid, accurate, and data-rich technologies. This technological pivot is a fundamental driver of investment and innovation across the entire food safety sector. Need a Customized Version? Request It Now: Post-Brexit Regulations and Future Trends Shaping the UK Food Safety Market The future of the UK food safety testing market will be shaped by an evolving regulatory framework and the continuation of current trends. Post-Brexit adjustments are creating new compliance hurdles and, consequently, new testing requirements. As of January 1, 2024, a significant new rule took effect. All pre-packaged food sold in Great Britain must now include a UK address for the Food Business Operator. The change introduces new labeling verification needs for the entire industry. Looking ahead, the market's growth trajectory appears strong and certain. The convergence of the key drivers—relentless pathogen pressure, expanding chemical threats, massive product recalls, tough enforcement, and public sector gaps—creates a compelling case for sustained investment. Businesses have no alternative but to integrate more frequent, more sophisticated, and more comprehensive testing into their operations. The demand is not just for testing, but for a true partnership in risk mitigation, making the UK food safety testing market a critical component of national food security and public health for years to come. UK Food Safety Testing Market Major Players: ALS Laboratories (UK) Limited Bureau Veritas UK Limited Campden BRI Group Eurofins Food Testing UK Limited Fera Science Limited Food Forensics Limited Intertek Group Plc. Northern Hygiene Laboratories Limited SGS United Kingdom Limited TÜV SÜD UK Limited Other Prominent Players Key Market Segmentation: By Test Method Microbiological Test Total Plate Count (TPC) Coliform Testing Listeria Testing Salmonella Testing Campylobacter Testing Sensory Test Manual Smell Taste Appearance Others Instrumental Smell Taste Appearance Others Physical Test Chemical Test Allergen Test Others By Product Type Processed Food Fruits &Vegetables Beverages Grains & Cereal Confectionery Meat & Meat Products Milk & Milk Products Others By Technology Traditional Testing Rapid Testing By Service Sourcing Inhouse Outsource By End User Food & Beverage Academic and Research Institutions Testing Laboratories Need a Detailed Walkthrough of the Report? Request a Live Session: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website:
Associated Press
11-08-2025
- Associated Press
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the second quarter ended June 30, 2025, and provided a general business update. 'This quarter, we remained on track with the strategic objectives we outlined at the start of the year, including the completion of enrollment in our pivotal Phase 3 PHOENIX trial — an important milestone in our development efforts for people living with geographic atrophy,' said Dr. Tom Lin, Chairman and CEO of Belite Bio. 'We also received Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease from the FDA, underscoring its potential as the first-ever treatment for this patient population and acknowledging the significant unmet need for people living with this debilitating disease. With the DRAGON trial on track to complete by the end of this year, we remain focused on advancing Tinlarebant toward key clinical and regulatory milestones.' Second Quarter 2025 Business Highlights and Upcoming Milestones: Clinical Highlights Tinlarebant (LBS-008) is an oral, potent, once-daily, retinol binding protein 4 (RBP4) antagonist that decreases RBP4 levels in the blood and reduces vitamin A (retinol) delivery to the eye without disrupting systemic retinol delivery to other tissues. Vitamin A is critical for normal vision but can accumulate as toxic byproducts in individuals affected with STGD1 and GA, the advanced form of dry age-related macular degeneration (AMD), leading to retinal cell death and loss of vision. Corporate Highlights Second Quarter 2025 Financial Results: Current Assets: As of June 30, 2025, the Company had $149.2 million in cash, liquidity funds, time deposits, and U.S treasury bills. R&D Expenses: For the three months ended June 30, 2025, research and development expenses were $11.0 million compared to $9.1 million for the same period in 2024. For the six months ended June 30, 2025, research and development expenses were $20.4 million compared to $15.8 million for the same period in 2024. The increase in research and development expenses in both the quarter and year-to-date was primarily attributable to (i) higher pass-through expenses related to the PHOENIX trial and manufacturing expenses payments, partially offset by lower DRAGON trial expenses and a development milestone payment for the completion of a phase 2 trial in 2024; (ii) an increase in share-based compensation expenses. G&A Expenses: For the three months ended June 30, 2025, general and administrative expenses were $6.5 million compared to $1.4 million for the same period in 2024. For the six months ended June 30, 2025, general and administration expenses were $12.7 million compared to $3.0 million for the same period in 2024. The increase in general and administrative expenses in both the quarter and year-to-date was primarily due to an increase in share-based compensation expenses. Other Income: For the three months ended June 30, 2025, other income was $1.3 million compared to $1.0 million for the same period in 2024. For the six months ended June 30, 2025, other income was $2.5 million compared to $1.4 million for the same period in 2024. The increase in both the quarter and year-to-date was attributed to interest from time deposits and U.S. treasury bills. Net Loss: For the three months ended June 30, 2025, the Company reported a net loss of $16.3 million, compared to a net loss of $9.5 million for the same period in 2024. For the six months ended June 30, 2025, the Company reported a net loss of $30.6 million, compared to a net loss of $17.4 million for the same period in 2024. Webcast Information Belite Bio will host a webcast on Monday, August 11, 2025, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update. To join the webcast, please visit A replay will be available for approximately 90 days following the event. About Belite Bio Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite's lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at Important Cautions Regarding Forward Looking Statements This press release contains forward-looking statements about future expectations and plans, as well as other statements regarding matters that are not historical facts. These statements include but are not limited to statements regarding the potential implications of clinical data for patients, and Belite Bio's advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates, and any other statements containing the words 'expect', 'hope' and similar expressions. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Belite Bio's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the timing to complete relevant clinical trials and/or to receive the interim/final data of such clinical trials; the timing to submit trial data to regulatory authorities for drug approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Belite Bio's drug candidates; the potential efficacy of Tinlarebant, as well as those risks more fully discussed in the 'Risk Factors' section in Belite Bio's filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Belite Bio, and Belite Bio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Media and Investor Relations Contact: Jennifer Wu [email protected] Julie Fallon [email protected]
Yahoo
09-08-2025
- Yahoo
I did the 90/90 hip stretch for a week — and my mobility improved in a way I didn't expect
When you buy through links on our articles, Future and its syndication partners may earn a commission. My challenges for Tom's Guide usually involve lifting weights, or using my body weight, to build strength and remind me I'm not in the enviable shape I think I am. The challenges are never less than interesting, they are often surprising, and some have impressed me to the point I have continued to use them in my exercise regime (you know when a move is right for you). So when my editor suggested the 90/90 stetch, I thought, 'This is different.' Then I thought, 'I wonder what it is.' This is not because I'm an ignoramus, but because, like most people, I don't stretch as much as I should. As someone interested in fitness and remaining physically strong, this is the strategy of, well, an ignoramus. So I was more than keen to give it a go. Was it a life-changing experience? I'm not a man given to hyperbole, so, no, of course not. Was it a revealing, fascinating, frustrating and, ultimately, greatly beneficial? It sure was. What is the 90/90 stretch? This is an immensely effective hip-mobility exercise. Most of us take our hips for granted, and it's only when we're dancing at a wedding that we realise they're not as loose as they once were, or ought to be. Hip mobility and flexibility are vital for general day-to-day activities, as well as for exercise and sports. However, because the muscles, tendons, and joints in the area simply do their job, we often assume they don't require attention. Out of sight, out of mind, until one day you drop your keys and are reduced to hoping someone short is nearby to pick them up for you. Good hip flexibility can also help relieve lower back pain, which, at any given time, afflicts about a quarter of US adults. The 90/90 works the hips internally and externally at the same time, which is rare for one move. It targets a variety of muscles, including the adductors, abductors, and glutes, as well as some of the hard-to-hit but important muscles such as the psoas and the piriformis. Crucially, it also works the hip capsule, specialised ligaments that stabilise the hip joint. This move asks a lot but boy, it delivers. How do I do the 90/90 stretch? Begin by sitting on the floor (I suggest you use a yoga mat for this move), with your right leg bent in front of you at a 90-degree angle, hip rotated out. This means the outside of your leg will be resting on the floor. Your foot should be in a neutral position, so don't point it. It, too, should form a 90-degree angle with your lower leg. Your thigh should be directly in front of your chest. If you feel you are leaning to the right, slide your leg slightly closer to your body, maintaining the angle as best you can. Position your left leg to your left side, again at a 90-degree angle, hip rotated internally. This means the inside of your leg will be resting on the floor. Make sure your back knee is in line with your hip. If you feel tightness in the hip, bring your leg forward a little, but again, maintain the angle. Keeping your legs in this position, and with your back straight, chest up, lean from the hips to feel a stretch through your right hip and glutes. Use your right arm to steady yourself as you increase the stretch. Breathe slowly and evenly, and hold the stretch for 60 seconds. Repeat on the other side and aim for two reps on each side. I did the 90/90 hip stretch every day for a week — here's what happened I admit I went into this challenge with the cockiness of the clueless. I figured that I'd have no trouble because I wasn't lifting, lowering, lunging, pushing, or otherwise using my muscles. And I already do some stretching. Not nearly enough, as it happens. Listen to your body On the first day, I got into position, though not as smoothly as I'd expected, as there is something counterintuitive about the shape the body makes with the two legs. It did not feel natural, and as I tried to relax and let my legs rest easily on the floor, I sensed a stretch not in my hips, but in my lower back and across my core. 'This can't be right,' I thought. It wasn't painful, but it was not the stretch I was expecting. I reset myself and tried again, but the result was the same. Afterwards, I decided my torso was twisting to maintain what I thought was the right position. Watch what you're doing On day two, I placed a two-foot mirror in front of me, and my indignity was complete. But I could immediately see that I was indeed leaning left or right, depending on which leg was in front. I corrected my position and held it for 40 seconds on each side, but while I felt a deep stretch, it was still not where it needed to be. And just like that… On day three, everything fell into place. I got into position, but shifted each leg slightly while holding the 90-degree angle, and I suddenly felt the stretch exactly where I was supposed to feel it, and not across the back or through the core. With this move, feel free to tweak things but maintain good form; you'll be amazed at the difference even a couple of inches makes. From the correct position, I was able to lean into the stretch and hold it for a minute on each side. I did this twice. Over the following few days, I increased the time to two minutes on each side, twice, paying attention to my breathing and always focusing on the location of the stretch. This move did not instantly improve hip mobility and flexibility, of course, but I did enjoy that deeply satisfying feeling of a stretch, and when I rose from my position, feeling fleetingly at one with my surroundings, I almost said 'Namaste.' Almost. Try this stretch I can't put it any plainer than that. I found it enormously beneficial for the entire hip area, but even getting into the correct position felt like a small triumph. I will continue to get myself into the right position, and even though I won't be able to see the benefits, I will know it's working. That said, I still refuse to dance. It's my gift to the world. Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button. More from Tom's Guide Forget tight hips — try these 5 mobility moves to unlock stiff hips and build stronger glutes I'm a personal trainer — here's 3 hip-opening exercises to reduce stiffness and boost lower-body mobility This routine is designed to improve your lower body's range of motion, increase blood flow and enhance joint mobility
